Evidence Review
H. pylori: from in vitro to clinical trials
The modern scientific interest in mastic gum began with a 1998 letter in the New England Journal of Medicine by Huwez et al., reporting that mastic killed H. pylori in vitro at concentrations as low as 125 µg/ml — a striking finding given the bacterium's role in peptic ulcers [1]. Subsequent mechanistic work by Marone et al. (2001) confirmed bactericidal activity against clinical H. pylori isolates with visible cellular destruction under electron microscopy. Paraschos et al. (2007) refined this further, identifying isomasticadienolic acid as a key active constituent and demonstrating ~30-fold reduction in H. pylori colony counts in a mouse gastric infection model after 3 months of treatment [3].
However, clinical translation has been inconsistent. Dabos et al. (2010) conducted a randomized pilot (n=52) comparing four groups: low-dose mastic alone (350 mg three times daily), high-dose mastic alone (1,050 mg three times daily), low-dose mastic plus pantoprazole, and standard triple therapy [2]. Eradication rates for mastic monotherapy were 31% (low dose) and 38% (high dose), compared to 77% for standard triple therapy. Unexpectedly, combining mastic with pantoprazole resulted in 0% eradication — the authors speculate the proton pump inhibitor may interfere with mastic's mechanism. Bebb et al. (2003, PMID 12888582) reported a fully negative result using 4 g/day for 14 days in 8 patients, with no change in ¹³C urea breath test scores, though this study was severely underpowered.
The most recent trial (Tulsian et al., 2026, PMID 41832367) tested mastic as an adjunct to bismuth quadruple therapy in 64 patients. Eradication rates improved from 67% (quadruple therapy alone) to 85% (quadruple therapy plus mastic), representing an 18% absolute improvement, though the pilot did not reach statistical significance (p=0.19). Symptom reduction was significantly greater in the mastic group (p=0.001). Overall: in vitro and animal evidence is strong; clinical data suggests modest but real activity, potentially more useful as adjunct therapy than as standalone treatment.
Gastric mucosal protection
Al-Said et al. (1986) conducted a systematic evaluation of mastic across six different ulcer induction models in rats [4]. Oral mastic at 500 mg/kg produced significant cytoprotection in all models tested: pyloric ligation-induced ulcers, aspirin-induced damage, phenylbutazone, reserpine, restraint/cold stress, and cysteamine-induced duodenal ulcers. Two mechanistic findings were notable: (1) pretreatment with indomethacin abolished the protective effect against ethanol-induced damage, implicating prostaglandin-mediated cytoprotection; (2) intraperitoneal administration showed no protection, indicating that direct mucosal contact is required. The resin also reduced free acidity in pylorus-ligated rats, suggesting a mild antisecretory component. While rat ulcer models have well-known translational limitations, the consistency across six different injury models strengthens the evidence for genuine cytoprotective activity.
Cardiovascular and metabolic effects
Triantafyllou et al. (2007) randomized 133 adults over 50 years of age to either high-dose mastic powder (5 g/day for 18 months) or a low-dose mastic solution (12 months) [5]. In the high-dose group, significant reductions were observed in total cholesterol, LDL cholesterol, total cholesterol-to-HDL ratio, lipoprotein(a), and the apolipoproteins apoA-1 and apoB. Liver enzyme markers — SGOT, SGPT, and gamma-GT — also declined, suggesting hepatoprotective activity. The low-dose group showed glucose reductions specifically in male participants. Effect sizes were not reported in detail, and the study lacked a true placebo arm for the high-dose group, which limits interpretation. Still, this remains the largest and longest human trial of mastic gum's metabolic effects.
Anti-inflammatory mechanism
Loizou et al. (2009) investigated mastic's anti-inflammatory effects in human aortic endothelial cells treated with TNF-α to simulate vascular inflammation [6]. Both crude mastic extract (25–200 µg/ml) and the isolated compound tirucallol (0.1–100 µM) dose-dependently reduced VCAM-1 and ICAM-1 expression — cell-surface adhesion molecules that facilitate monocyte recruitment, an early step in atherosclerotic plaque formation. Monocyte adhesion to activated endothelial cells was correspondingly reduced. The mechanism involved attenuated phosphorylation of NF-κB p65. This molecular data complements the human lipid trial and suggests mastic may act on multiple cardiovascular risk pathways simultaneously.
Strength of evidence summary
The totality of evidence supports mastic gum's role as a gastric-protective and mildly antibacterial agent with additional anti-inflammatory properties. The H. pylori data is compelling mechanistically but inconsistent clinically — monotherapy achieves 31–38% eradication in the most favorable trial, which is insufficient as sole treatment for active infection. Gastric cytoprotection is well-supported in animal models through a plausible prostaglandin-dependent mechanism. The human cardiovascular trial (n=133) provides the strongest clinical evidence for systemic benefits, though it requires replication with better controls. No serious safety concerns have emerged across trials at doses up to 5 g/day over 18 months.